Assessing minimal residual disease in chronic lymphocytic leukemia

Current Hematologic Malignancy Reports

Volumn 3, Issue 1, 2008, Pages 47-53

  Rawstron, Andy C ^a   Hillmen, Peter ^b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; HUMAN; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; QUALITATIVE ANALYSIS; QUANTITATIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM, RESIDUAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 41849143016     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-008-0008-8     Document Type: Review

References (35)

1. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
2. Keating MJ, O'Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
3. Wierda W, O'Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070-4078.
4. Robertson LE, Huh YO, Butler JJ, et al.: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80:29-36.
5. Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002, 119:976-984.
6. Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979. Assesses the potential to guide patients to an MRD-negative CR and demonstrates a significant improvement in overall and progression-free survival for patients achieving eradication of residual disease.
7. Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997.
8. Robak T, Blonski JZ, Kasznicki M, et al.: Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002, 3:244-250.
9. Montillo M, Tedeschi A, Miqueleiz S, et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006, 24:2337-2342.
10. Del Poeta G, Del Principe MI, Consalvo MA, et al.: The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005, 104:2743-2752.
11. Wendtner CM, Ritgen M, Schweighofer CD, et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18:1093-1101.
12. O'Brien SM, Kantarjian HM, Thomas DA, et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98:2657-2663.
13. Elter T, Borchmann P, Schulz H, et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024-7031.
14. Milligan DW, Fernandes S, Dasgupta R, et al.: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005, 105:397-404.
15. Moreno C, Villamor N, Colomer D, et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 107:4563-4569. Provides a direct comparison of different MRD techniques and their clinical implications in autologous and allogeneic SCT.
16. Moreno C, Villamor N, Colomer D, et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3433-3438.
17. Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004, 104:2600-2602.
18. Sorror ML, Maris MB, Sandmaier BM, et al.: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23:3819-3829.
19. Caballero D, Garcia-Marco JA, Martino R, et al.: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005, 11:7757-7763.
20. Cabezudo E, Matutes E, Ramrattan M, et al.: Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997, 11:1909-1914.
21. Bomberger C, Singh-Jairam M, Rodey G, et al.: Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood 1998, 91:2588-2600.
22. Vuillier F, Claisse JF, Vandenvelde C, et al.: Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992, 7:195-204.
23. Bottcher S, Ritgen M, Pott C, et al.: Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18:1637-1645.
24. Rawstron AC, Kennedy B, Evans PA, et al.: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
25. Davies FE, Forsyth PD, Rawstron AC, et al.: The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001, 112:814-819.
26. Garcia VJ, Delgado I, Benito L, et al.: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia 1999, 13:1501-1505.
27. Esteve J, Villamor N, Colomer D, et al.: Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001, 15:445-451.
28. Maloum K, Sutton L, Baudet S, et al.: Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol 2002, 119:970-975.
29. Rawstron AC, Villamor N, Ritgen M, et al.: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007, 21:956-964. Provides an extensive comparison of different antibodies for detection of MRD in CLL and discusses development of a standard method that can detect CLL cells at the 0.01% level with known specificity and sensitivity.
30. van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, et al.: Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007, 21:706-713.
31. van der Velden VH, Cazzaniga G, Schrauder A, et al.: Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611.
32. Gribben JG, Zahrieh D, Stephans K, et al.: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
33. Rawstron AC, Kennedy B, Moreton P, et al.: Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004, 103:2027-2031.
34. de Tute RM, Jack AS, Child JA, et al.: A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007, 21:2046-2049.
35. Pekova S, Markova J, Pajer P, et al.: Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn 2005, 9:23-34.